Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models.

ABSTRACT:

Background

Concurrent KRAS LKB1 (STK11, KL) mutant non-small cell lung cancers (NSCLC) do not respond well to current immune checkpoint blockade therapies, however targeting major histocompatibility complex class I-related chain A or B (MICA/B), could pose an alternative therapeutic strategy through activation of natural killer (NK) cells.

Methods

Expression of NK cell activating ligands in NSCLC cell line and patient data were analyzed. Cell surface expression of MICA/B in NSCLC cell lines was determined through flow cytometry while ligand shedding in both patient blood and cell lines was determined through ELISA. We engineered an antibody-dependent cellular cytotoxicity (ADCC) enhanced MICA/B monoclonal antibody, AHA-1031, which prevents ligand shedding without inte

SUBMITTER: Kowash RR 

PROVIDER: S-EPMC11749492 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature